Skip to main contentAI and Advanced
/
PFIZER · NSEBSE SENSEX74,501.11+0.25%BSE |
NIFTY 5023,326.3+0.24%NSE |
NIFTY BANK56,243.75+0.34%NSE |
NIFTY IT28,759.45-1.36%NSE |
NIFTY AUTO27,253.5+0.35%NSE |
NIFTY FMCG45,695.45+0.27%NSE |
NIFTY PHARMA26,694.3+0.43%NSE |
NIFTY 50022,770.3+0.51%NSE |
PF
NSE · Equity shares · Major Drugs-27.20 · -0.67%
Pfizer PFIZER
NSE:INR 4,014.4
BSE:INR 4,012
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for PFIZER
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 4,041.6
Day rangeINR 3,955.5 — INR 4,080
52-week rangeINR 3,955.5 — INR 5,878.55
Volume37,280
Market cap22,334.85
P/E27.63
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,519.65
Net Income (INR Cr)722.43
Rev Growth (5 Year %)2.39
EPS Growth (5 Year %)7.74
P/E Ratio27.63
EPS165.87
Research path: Interpret Pfizer's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
PFIZERPfizer1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 4,921.88 | 4,911.11 | 4,228.78 |
| Cash Equivalents | 3,110.76 | 493.12 | 107.66 |
| Other Liabilities Total | 55.42 | 56.57 | 32.33 |
| Common Stock Total | 45.75 | 45.75 | 45.75 |
| Other Current Assets Total | 35.03 | 13.49 | 14.28 |
| Total Assets | 4,921.88 | 4,911.11 | 4,228.78 |
| Current Portof LT Debt/Capital Leases | 31.65 | 38.28 | 37.69 |
| Total Equity | 4,202.9 | 4,217.41 | 3,595.54 |
| Long Term Investments | 15.19 | 13.93 | 14.28 |
| Retained Earnings(Accumulated Deficit) | 4,157.15 | 2,838.92 | 2,217.79 |
| Total Common Shares Outstanding | 4.57 | 4.57 | 4.57 |
| Tangible Book Valueper Share Common Eq | 800.27 | 801.27 | 663.15 |
| Goodwill Net | 527.49 | 527.49 | 527.49 |
| Total Liabilities | 718.98 | 693.7 | 633.24 |
| Total Debt | 70.23 | 108.4 | 94.54 |
| Short Term Investments | 2.97 | 2,290.4 | 1,917.46 |
| Cashand Short Term Investments | 3,113.73 | 2,788.45 | 2,034.05 |
| Total Receivables Net | 181.8 | 214.7 | 239.85 |
| Notes Payable/Short Term Debt | 2.5 | 2.5 | 2.5 |
| Accounts Receivable-Trade Net | 181.8 | 193.09 | 187.61 |
| Property/Plant/Equipment Total-Net | 156.13 | 179.46 | 151.35 |
| Total Current Liabilities | 627.48 | 569.51 | 546.56 |
| Total Inventory | 472.66 | 487.29 | 441.62 |
| Accounts Payable | 215.94 | 151.6 | 166.23 |
| Other Currentliabilities Total | 377.39 | 352.62 | 320.57 |
| Total Long Term Debt | 36.08 | 67.62 | 54.35 |
| Intangibles Net | 14.35 | 24.31 | 34.27 |
| Other Long Term Assets Total | 239.17 | 75.53 | 137.86 |
| Note Receivable-Long Term | 166.33 | 577.54 | 625.72 |
| Total Current Assets | 3,803.22 | 3,512.85 | 2,737.81 |
| Capital Lease Obligations | 36.08 | 67.62 | 54.35 |
| Accumulated Depreciation Total | Not available | -301.44 | -259.56 |
| Accrued Expenses | Not available | 24.51 | 19.57 |
| Other Equity Total | Not available | 12.07 | 11.33 |
| Prepaid Expenses | Not available | 8.92 | 8.01 |
| Additional Paid-In Capital | Not available | 1,320.67 | 1,320.67 |
| Cash | Not available | 4.93 | 8.93 |
| Property/Plant/Equipment Total-Gross | Not available | 473.26 | 410.51 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio6.1
Price to Sale Ratio8.86
Growth
Debt 5Yr CAGR %-7.89
Margins
Operating Margin 12m32.49
Operating Margin 5y Avg29.58
Net Profit Margin 12m28.61
Net Profit Margin 5y27.25
Yield
Dividend Yield %1.53
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk25.64
Analyst consensus
ConsensusStrong Buy
Consensus score1.60
Analyst opinions5
Strong Sell count0
Sell count0
Hold count1
Buy count1
Strong Buy count3
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Aurobindo Pharma | INR 1,589.5 | 91,456.32 | 25.09 | — |
| Neuland Laboratories | INR 21,645 | 27,583.36 | 64.28 | — |
| Unichem Laboratories | INR 493.05 | 3,476.61 | 54.27 | — |
| Jagsonpal Pharmaceuticals | INR 236.75 | 1,560.88 | 34.27 | — |
| Themis Medicare | INR 112.65 | 1,035.27 | 632.19 | — |
Shareholding
Ownership
- Promoter
- 63.92%
- FII
- 1.65%
- MF
- 12.68%
- Other
- 21.75%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Pfizer India clarifies Premarin Vaginal Cream temporarily discontinued due to supply constraints - Indian Pharma PostMarket news · 20 Jul 2026, 8:32 am
Pfizer India clarifies Premarin Vaginal Cream temporarily discontinued due to supply constraints Indian Pharma Post
Pfizer Ltd. Technical Momentum Shifts to Bearish Amid Market Pressure - MarketsMojoMarket news · 20 Jul 2026, 8:04 am
Pfizer Ltd. Technical Momentum Shifts to Bearish Amid Market Pressure MarketsMojo
Pfizer Halts Premarin Cream Sales in India Due to Supply Issues - WhalesbookMarket news · 17 Jul 2026, 5:56 am
Pfizer Halts Premarin Cream Sales in India Due to Supply Issues Whalesbook
EXCLUSIVE: Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges - ReutersMarket news · 17 Jul 2026, 3:13 am
EXCLUSIVE: Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges Reuters
Pfizer Ltd. is Rated Sell by MarketsMOJO - MarketsMojoMarket news · 17 Jul 2026, 2:22 am
Pfizer Ltd. is Rated Sell by MarketsMOJO MarketsMojo
There May Be Some Bright Spots In Pfizer's (NSE:PFIZER) Earnings - simplywall.stMarket news · 14 Jul 2026, 6:37 am
There May Be Some Bright Spots In Pfizer's (NSE:PFIZER) Earnings simplywall.st
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.75.0000 per share(750%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Pfizer
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approved for administering to individuals of all ages against pneumococcal disease, an infection caused by streptococcus pneumoniae bacteria. Internal Medicine portfolio includes approximately 17 specialties and seven therapy areas, including respiratory, multivitamin and multimineral, gastrointestinal, pain, neuroscience, cardiovascular and women’s healthcare. Pfizer Hospital Business Unit focuses on providing advanced anti-infectives to institutions such as hospitals and nursing homes. Inflammation and Immunology focuses on discovering and developing novel therapeutics for chronic autoimmune diseases. Its brands include Prevenar13, CorexDX, Dolonex, Enbrel, Becosules and Folvite, among others.
Company facts
- Industry
- Major Drugs
- Sector
- Major Drugs
- NSE Code
- PFIZER
- BSE Code
- 500680
Questions
Stock FAQ
What is the symbol and ISIN of Pfizer?
Pfizer has the symbol PFIZER and ISIN - INE182A01018.
What is the current price of Pfizer?
Pfizer is currently trading at INR 4,014.40.
What are the year high and year low of Pfizer?
Pfizer has a year high of INR 5,878.55 and a year low of INR 3,955.50.
What is the market capitalization of Pfizer?
Pfizer has a market capitalization of INR 22,334.85 crore.
What is the P/E ratio of Pfizer?
Pfizer has a P/E ratio of 27.63.
What is the dividend yield of Pfizer?
Pfizer has a dividend yield of 1.53%.
How is the financial performance of Pfizer based on revenue, net income, and EPS?
Pfizer has revenue of INR 2,519.65 crore, net income of INR 722.43 crore, and EPS of INR 168.63.
What is the book value of Pfizer?
Pfizer has a book value of NA.
What is the debt-to-equity ratio of Pfizer?
Pfizer has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Pfizer?
Pfizer has a price-to-book ratio of NA and a price-to-sales ratio of 8.86.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.